Cancer is one of the most deadly diseases with over 8 million deaths in 2012 worldwide, highlighting the importance to develop novel therapeutics to improve the survival of patients. A new and very promising approach is cancer immunotherapy. Immune checkpoint blocking antibodies are achieving remarkable responses in a fraction of cancer patients across several tumour types. However, many patients do not respond or acquire resistance.
The Oncology and Cellular Immunology Laboratory is particularly interested in how innate immune cells contribute to resistance to current immunotherapies. Its team aims to understand the cellular and molecular mechanism to identify novel targets. For this, genetically engineered and transplantable mouse models of cancer, state-of-the art flow cytometry, imaging as well as next generation sequencing techniques are commonly used.
The Laboratory is operating in an intellectually inspiring environment, providing excellent training in tumour immunology and biology to give emerging young scientist the best possible opportunities for their career development. Honours, Master and PhD students are welcomed to express their interest in cutting edge medical research.
Team Head: Dr Tobias Bald
- Dr Tobias Bald, Team Head
- Sophie Krumeich, Scientific Technical Officer
- Ashmitha Sundarrajan, Research Assistant
- Dillon Corvino, Research Assistant
- Bryce Thomas, Research Assistant
- Maria Villacanas-Jorge, Masters Student
Selected Key Publications
Glodde N.* and Bald T.* et al., (2017) Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017 Oct 17;47(4):789-802.e9
Bald T. et al., (2014) Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, 4:674-87.
Bald T. et al., (2014). Ultraviolet radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature, 507, 109-13.
If you wish to apply for QIMR Berghofer's student program,
click here for more information.